EP2188302

GENENTECH, INC.
Application Number
EP08781481A
Filing Date
Jul 8, 2008
Status
Granted And Under Opposition
Sep 29, 2017
Grant Date
Nov 1, 2017
External Links
Slate, Register

Biblio Summary

The patent EP2188302B1 was granted on Nov 1, 2017 by Genentech, Inc. The patent is currently Granted And Under Opposition.

The table below shows 11 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJan 22, 2020INTERVENTION ADMISSIBLE
DF-MP DORRIES FRANK-MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBBAug 1, 2018ADMISSIBLE
HOFFMANN EITLEAug 1, 2018ADMISSIBLE
MAIWALD GMBHAug 1, 2018ADMISSIBLE
MATHYS & SQUIRE LLPAug 1, 2018ADMISSIBLE
MERCK SHARP & DOHME LLCAug 1, 2018ADMISSIBLE
OETKE, CORNELIAAug 1, 2018ADMISSIBLE
DR. H. ULRICH DORRIESAug 1, 2018WITHDRAWN
BAYER INTELLECTUAL PROPERTY GMBHJul 31, 2018ADMISSIBLE
GRUNECKER PATENT- UND RECHTSANWALTE PARTG MBBJul 30, 2018ADMISSIBLE
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJul 30, 2018ADMISSIBLE

The table below shows the patents of Genentech, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2694072Combinations Of Akt Inhibitor Compounds And Abiraterone, And Methods Of UseAug 7, 20241
EP4108259Process For Concentration Of Antibodies And Therapeutic Products ThereofJan 3, 20241
EP3589661Adjuvant Treatment Of Her2-Positive Breast CancerNov 1, 20234